期刊文献+

大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病的保护作用 被引量:20

Effect of high dose atorvastatin combined with hydratin in preventing contrast induced nephropathy in elderly patients underwent primary PCI
原文传递
导出
摘要 目的探讨阿托伐他汀(80 mg)联合水化对老年(年龄≥60岁)急诊冠状动脉介入术(PCI)术后造影剂肾病的保护作用。方法 92例患者随机分为大剂量强化治疗组、常规剂量治疗组、空白对照组,3组患者在水化治疗的基础上,大剂量强化治疗组:入院后口服阿托伐他汀80 mg,急诊PCI术后3 d内口服阿托伐他汀40 mg.d-1;常规剂量治疗组:入院后口服阿托伐他汀20 mg,急诊PCI术后3 d内口服阿托伐他汀20 mg.d-1;空白对照组:术前未给予他汀类药物。分别测定3组患者术后24,72 h的血肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)以及造影剂肾病的发生率。结果急诊PCI术后24 h与PCI术前相比,大剂量强化治疗组BUN,Scr的增加值较常规剂量治疗组小,差异有统计学意义(P<0.05)。急诊PCI术后72 h与PCI术前相比,大剂量强化治疗组BUN,Scr的增加值以及Ccr的下降值明显低于常规剂量治疗组(P<0.05)。结论大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病具有一定的保护作用。 Objective To investigate protection effect of high dose sta tions(80 rag) combined with hydration in elderly patients on contrast in duced nephropathy after primary percutaneous coronary intervention (PCI). Methods Before primary PCI,92 case with acute myocardial infarction were divided into three groups:high dose atorvastatin group, regular dose atorvastatin group and blank control group. On the basis of the hydration therapy, the patients of high dose atorvastatin group re ceived atorvastatin 80 mg orally instantly before primary PCI and 40 mg once a day after primary PCI procedure for three days. The patients of regular dose atorvastatin groups received atorvastatin 20 mg orally instant ly before primary PCI and once a day after primary PCI procedure for three days . Then BUN, Scr, Ccr and incident rate of CIN were measured and compared 24,72 h after primary PCI between groups. Results In creased value of BUN and Scr in high dose group at 24 h post primary PCI were significantly lower than regular group when compare with before primary PCI (P〈0. 05). Increased value of BUN and Scr in high dose group at 72 h were significantly lower than regular group either when compare with before primary PCI ( P 〈 0.05 ). Conclusion High dose atorvastatin combined with hydration can he of some preventive and pro tective value to CIN for the elderly patients after primary PCI.
作者 何贵新
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第8期578-580,605,共4页 The Chinese Journal of Clinical Pharmacology
关键词 阿托伐他汀 急性心肌梗死 造影剂肾病 保护作用 atorvastatin acute myocardial infarction contrast induced nephopathy protection
  • 相关文献

参考文献10

  • 1姜文兵,傅国胜.造影剂肾病预防的研究进展[J].临床荟萃,2006,21(12):897-900. 被引量:23
  • 2Lecian D,Demova H,Lodererova A,et al. Renal effects of HMG - CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis[ J]. Kidney Blood Press Res ,2006 ;29 : 135 - 143.
  • 3Ma YC, Zuo L, Chen JH. et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kid - hey dis- ease [ J . J Am Soc Nephrol ,2006 ; 17 : 2937 - 2944.
  • 4Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic im- portance of acute renal failure after percutaneous coronary interven- tion [ J]. Circulation ,2002 ; 105:2259 - 2564.
  • 5Asif A,Epstein M. Prevention of radioncontrast - induced nephrops - thy [ J ]. Am J Kidney Dis,2004 ;44 : 12.
  • 6Attallah N, Yassine L,Musial J, et al. The potential role of statins in.contrast nephropathy[ J]. Clin Nephm1,2004 ;62:273 - 278.
  • 7Ozhan H, Erden I, Ordu S, et al. Efficacy of short - term high - dose atorvastatin for prevention of contrast--induced nephropathy in pa- tients undergoing coronary [ J ]. Angiolngy, 2010 61:711 - 714.
  • 8Melfi R, Nusca A, Patti G, et al. Statins and their role in prepercuta- neous coronary intervention [ J ]. Curt Cardiol Rep, 2010 ; 12 : 295 - 301.
  • 9. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast -induced nephropathy and to improve long- term outcome in patients undergoing percutaneous coronary interven- tion[J]. Am J Cardiol ,2008 ; l O1:279 -285.
  • 10. Patti P, Nusca A, Chello M, et al. Useflalness of statin pretreatment to prevent contrast - induced nephropathy and to improve long - term outcome in patients undergoing percutaneous coronary interven- tion[ J]. Am J Cardiol,2008 ; lO1:279 -285.

二级参考文献26

  • 1Zager RA,Johnson AC,Hanson SY.Radiographic contrast media-induced tubular injury:evaluation of oxidant stress and plasma membrane integrity[J].Kidney Int,2003,64(1):128-139.
  • 2Alonso A,Lau J,Jaber BL,et al.Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease:a meta-analysis of randomizes,controlled trials[J].Am J Kidney Dis,2004,43(1):1-9.
  • 3Isenbarger DW,Kent SM,O'Malley PG.Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy[J].Am J Cardiol,2003;92(12):1454-1458.
  • 4Birck R,Krzossok S,Markowetz F,et al.Acetylchsteine for prevention of contrast nephropathy:meta analysis[J].Lancet,2003,362(9384):598-603.
  • 5Briguori C,Colombo A,Violante A,et al.Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity[J].Eur Heart J,2004,25(3):206-211.
  • 6Goldenberg I,Shechter M,Matetzky S,et al.Oral acetylcysteine as an adjunt to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography.A randomized controlled trial and review of the current literature[J].Eur Heart J,2004,25(3):212-218.
  • 7Esnault VL.Radiocontrast media-induced nephrotoxicity in patients with renal failure:rationale for a new double-blind,prospective,randomized trial testing calcium channel antagonists[J].Nephrol Dial Transplant,2002,17(8):1362-1364.
  • 8Oldroyd SD,Morcos SK.Endothelin:what does the radiologist need to know?[J].Br J Radiol,2000,73(876):1246-1251.
  • 9Wang A,Holcslow T,Bashore TM,et al.Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism[J].Kidney Int,2000,57(4):1675-1680.
  • 10Kini AS,Mitre CA,Kamran M,et al.Changing trends in incidence and percutaneous coronary intervention with use of fenoldopam[J],2002,89(8):999-1002.

共引文献22

同被引文献208

引证文献20

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部